We would like to inform you that the Board Meeting of the Company was held today i.e. on Tuesday, May 12, 2026, at the registered office of the Company. In pursuance of Regulation 30 and ....
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma's Board approved audited standalone and consolidated financial results for Q4 and year ended March 31, 2026. Standalone net profit grew to Rs. 9,687.44 lakh (from Rs. 8,116.81 lakh), while consolidated net profit reached Rs. 8,429.93 lakh. Total standalone income was Rs. 84,621.91 lakh, up from Rs. 71,816.45 lakh in the previous year. The statutory auditor issued an unmodified (clean) opinion on both standalone and consolidated results. The Board recommended a final dividend of Rs. 1 per share (100% on face value of Rs. 1). BDO India Services Private Limited was reappointed as internal auditor for FY 2026-27. The 41st AGM is scheduled for July 15, 2026.
Clean audit opinion and strong profit growth indicate healthy financial position. Dividend declaration provides shareholder returns. The stock may see positive reaction given improved profitability and clean audit status.